RxDoctor Payments Data

Andrea Varga, MD

Internal Medicine · Sarasota, FLNPI 1336133842

Payments from drug & device makers

$980in general payments, 2019–2025

Across 12 payments — averaging $81.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$242
  • GSK$237
  • Centinel Spine, LLC$155
  • AstraZeneca$125
  • Novo Nordisk$122
  • Medtronic$63
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$980100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC3$242
GSK3$237
Centinel Spine, LLC1$155
AstraZeneca1$125
Novo Nordisk1$122
Medtronic1$63
Abbott1$19
Pfizer1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$980 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$224,724
Medicare patients
688
Services billed
2,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$84,814
OzempicSemaglutide77$78,208
FarxigaDapagliflozin Propanediol14$22,496
JanuviaSitagliptin Phosphate15$19,749
XareltoRivaroxaban14$17,233
JardianceEmpagliflozin12$16,892
VascepaIcosapent Ethyl11$7,934
Atorvastatin Calcium596$4,890
Rosuvastatin Calcium316$4,039
Losartan Potassium276$2,589
SynthroidLevothyroxine Sodium36$2,536
Levothyroxine Sodium303$2,421
Omeprazole145$2,031
Azelastine Hcl64$1,463
Potassium Chloride74$1,451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$84,81474 claims
Novo NordiskOzempic$122$78,20877 claims
AstraZenecaFarxiga$125$22,49614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →